EPRX fundamentals
An in-depth look to EUPRAXIA PHARMACEUTICALS INC operating, investing, and financing activities
EPRX free cash flow for Q1 24 is -8.26 M CAD. For 2023, EPRX free cash flow was -28.02 M CAD and operating cash flow was -27.92 M CAD.
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q1 '24
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: CAD
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q1 '24
TTM